Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Theriva Biologics, Inc. is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 3 distinct examiners, ensuring that no two pending matters are being reviewed by the same person. Furthermore, the workload is spread across 3 distinct art units, which suggests a high degree of technical specialization for each individual application.
DAVIS, RUTH A is the busiest examiner for the portfolio, holding 1 pending action. With a busiest examiner pending count of 1 and a total of 3 pending office actions, the company's prosecution efforts are distributed across the distinct examiners. This structure means that the company's overall success is not tied to the discretion of a single examiner. Instead, the 3 pending office actions are subject to the independent standards of the distinct art units. Practitioners should be prepared to tailor their arguments to the specific requirements of each of the 3 distinct examiners involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAVIS, RUTH A | 1 | 60.8% | +31.1% |
| IANNUZO, NATALIE NMN | 1 | 12.5% | +71.4% |
| DURYEE, ALEXANDER MARSH | 1 | 33.3% | +41.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18563277 | ALKALINE PHOSPHATASE-BASED TREATMENTS OF CELIAC DISEASE | DAVIS, RUTH A | 22d overdue |
| 17725692 | ALKALINE PHOSPHATASE AGENTS FOR TREATMENT OF NEURODEVELOPMENTAL DISORDERS | IANNUZO, NATALIE NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18563277 | ALKALINE PHOSPHATASE-BASED TREATMENTS OF CELIAC DISEASE | DAVIS, RUTH A | 22d overdue |
| 17725692 | ALKALINE PHOSPHATASE AGENTS FOR TREATMENT OF NEURODEVELOPMENTAL DISORDERS | IANNUZO, NATALIE NMN | — |
| 17626932 | INTESTINAL ALKALINE PHOSPHATASE-BASED TREATMENTS OF METABOLIC DISORDERS | DURYEE, ALEXANDER MARSH | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| 1653 | 1 |
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18563277 | ALKALINE PHOSPHATASE-BASED TREATMENTS OF CELIAC DISEASE | DAVIS, RUTH A | 1699 | §103§112Other | Final Rejection | 22d overdue | Pending | Nov 21, 2023 |
| 17725692 | ALKALINE PHOSPHATASE AGENTS FOR TREATMENT OF NEURODEVELOPMENTAL DISORDERS | IANNUZO, NATALIE NMN | 1653 | §103§112 | Non-Final OA | — | Pending | Apr 21, 2022 |
| 17626932 | INTESTINAL ALKALINE PHOSPHATASE-BASED TREATMENTS OF METABOLIC DISORDERS | DURYEE, ALEXANDER MARSH | 1657 | §103 | Final Rejection | — | Pending | Jan 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial